Lack of CD8
HIV-1
KSHV
Kaposi’s sarcoma
immune cells
tumor microenvironment
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
28 Apr 2020
28 Apr 2020
Historique:
received:
18
02
2020
accepted:
03
04
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
Despite the close association between Kaposi's sarcoma (KS) and immune dysfunction, it remains unclear whether tumor infiltrating immune cells (TIIC), by their absence, presence, or dysfunction, are mechanistically correlated with KS pathogenesis. Therefore, their potential capacity to serve as prognostic biomarkers of KS disease progression or control is unclear. Because epidemic-KS (EpKS) occurs with HIV-1 co-infection, it is particularly important to compare TIIC between EpKS and HIV-negative African endemic-KS (EnKS) to dissect the roles of HIV-1 and Kaposi Sarcoma-associated herpesvirus (KSHV) in KS pathogenesis. This cross-sectional study of 13 advanced KS (4 EnKS, 9 EpKS) patients and 3 healthy controls utilized single-color immunohistochemistry and dual-color immunofluorescence assays to characterize and quantify KSHV infected cells in relation to various TIIC in KS biopsies. Analysis of variance (ANOVA) and Mann-Whitney tests were used to assess differences between groups where
Identifiants
pubmed: 32391124
doi: 10.18632/oncotarget.27569
pii: 27569
pmc: PMC7197452
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1556-1572Subventions
Organisme : FIC NIH HHS
ID : K43 TW011418
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228178
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA221204
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The funders played no role in design of the study, the collection, analysis or interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication. We declare that we have no conflict of interest.
Références
Oncoimmunology. 2019 Apr 3;8(7):1593806
pubmed: 31143514
Br J Cancer. 1998 Dec;78(11):1521-8
pubmed: 9836488
Am J Pathol. 2015 Feb;185(2):314-24
pubmed: 25432064
J Immunol. 2010 May 1;184(9):5186-92
pubmed: 20357254
J Infect Dis. 2019 Apr 8;219(8):1318-1328
pubmed: 30452681
Cell Metab. 2019 Jun 4;29(6):1376-1389.e4
pubmed: 30930171
Exp Cell Res. 2009 May 15;315(9):1593-600
pubmed: 19013150
J Cell Biol. 2001 Dec 24;155(7):1265-73
pubmed: 11756476
Oncotarget. 2017 Nov 25;8(65):109402-109416
pubmed: 29312617
BMC Res Notes. 2015 Sep 15;8:440
pubmed: 26374100
Oncotarget. 2015 Apr 30;6(12):10592-603
pubmed: 25871392
Br J Cancer. 2008 Sep 2;99(5):800-4
pubmed: 18665172
Viruses. 2014 Dec 11;6(12):4961-98
pubmed: 25514370
Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
J Virol. 2017 Nov 30;91(24):
pubmed: 28978712
Mediators Inflamm. 2017;2017:9624760
pubmed: 28210073
Cancer Med. 2019 Aug;8(10):4709-4721
pubmed: 31222971
J Infect Dis. 2017 Jun 15;215(12):1898-1907
pubmed: 27932611
J Virol. 2017 Sep 27;91(20):
pubmed: 28768873
J Immunol Res. 2018 Jun 5;2018:7590350
pubmed: 29967802
Immunol Rev. 2005 Oct;207:112-25
pubmed: 16181331
AIDS Res Hum Retroviruses. 2017 Jul;33(7):668-674
pubmed: 28121161
PLoS One. 2018 Jul 24;13(7):e0201325
pubmed: 30040863
Trends Cell Biol. 2013 Sep;23(9):421-32
pubmed: 23685018
Front Immunol. 2018 Jan 22;9:14
pubmed: 29403496
Nephrol Dial Transplant. 2002 May;17(5):892-6
pubmed: 11981080
Front Oncol. 2018 Mar 02;8:44
pubmed: 29552542
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Sci Rep. 2017 Aug 8;7(1):7525
pubmed: 28790445
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16519-16528
pubmed: 31363046
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Brief Funct Genomics. 2019 Mar 22;18(2):99-106
pubmed: 29554204
Sci Rep. 2017 May 11;7(1):1755
pubmed: 28496107
Cancer Res. 2018 Jan 1;78(1):230-245
pubmed: 29066510
Cancer Manag Res. 2018 Sep 13;10:3505-3511
pubmed: 30271199
Int J Cancer. 2019 Nov 1;145(9):2468-2477
pubmed: 31265124
Nat Immunol. 2008 Sep;9(9):970-80
pubmed: 18711434
Cell Metab. 2019 Jun 4;29(6):1390-1399.e6
pubmed: 30827862
Oncol Lett. 2019 May;17(5):4155-4161
pubmed: 30944610
J Virol. 2011 May;85(9):4530-7
pubmed: 21345951
PLoS One. 2011;6(5):e19968
pubmed: 21625498
BMC Biol. 2017 Jun 29;15(1):53
pubmed: 28662662
J Infect Dis. 2018 Sep 22;218(9):1453-1463
pubmed: 29868826
Oncotarget. 2017 Aug 14;8(50):87244-87262
pubmed: 29152078
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13
pubmed: 30581539
Angiogenesis. 2015 Oct;18(4):477-88
pubmed: 26092770
Cancer Immun. 2007 Feb 21;7:3
pubmed: 17311362
J Virol. 2019 Jul 30;93(16):
pubmed: 31142670
Cancer Res. 2016 Feb 1;76(3):513-6
pubmed: 26772756
Adv Virol. 2010;2010:340356
pubmed: 22331985
PLoS Pathog. 2018 Jan 19;14(1):e1006844
pubmed: 29352292
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737